

# AURINIA PHARMACEUTICALS INC.

ISIN: CA05156V1022 WKN: 05156V102 Asset Class: **Stock**

## Company

2024/04/16 22:00:00



Price

**5.00** USD

Difference ▼ -0.79% (-0.04)



## Contact Details

AURINIA  
PHARMACEUTICALS INC.

Tel: +1-250-744-2487

--

Fax: +1-250-708-4345

14315 118 Avenue, Suite 140

Web:

<http://www.auriniapharma.com>

T5L 4S6 Edmonton

E-mail: -

## Company Profile

Aurinia Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.

## Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
<b>Current assets</b>	424,800,000		442,539,000		513,324,000	
<b>Common stock capital</b>		1,200,218,000		1,185,309,000		1,177,051,000
<b>Fixed assets</b>	123,262,000		28,321,000		30,043,000	
<b>Equity capital of a company</b>		377,954,000		405,435,000		479,091,000
<b>Cash and cash equivalents</b>	48,875,000		94,172,000		231,900,000	
<b>Accrued liabilities</b>		0		0		0
<b>Other assets</b>	-		-		-	
<b>Current liabilities</b>		77,188,000		46,107,000		40,646,000
<b>Prepayments and accrued income</b>	-		-		-	
<b>Non-current liabilities</b>		92,920,000		19,318,000		23,630,000
<b>Different income</b>		-		-		-
<b>Other liabilities</b>		10,911,000		12,166,000		15,950,000
<b>Total assets</b>	548,062,000	548,062,000	470,860,000	470,860,000	543,367,000	543,367,000

## Balance notes

	2023	2022	2021
<b>Accounting standard</b>	US-GAAP	US-GAAP	US-GAAP
<b>Employees</b>	300	300	300
<b>Equity ratio</b>	68.96%	86.11%	88.17%
<b>Debt-equity ratio</b>	45.01%	16.14%	13.42%

## Others

	2023	2022	2021
<b>Tax Expense Rate</b>	-0.71%	-1.72%	-0.42%

# AURINIA PHARMACEUTICALS INC.

ISIN: CA05156V1022 WKN: 05156V102 Asset Class: Stock

## Income statement

	2023	2022	2021
<b>Turnover</b>	175,513,000	134,030,000	45,605,000
<b>Net income</b>	-78,020,000	-108,180,000	-180,966,000
<b>EBIT</b>	-85,483,519	-103,923,481	-168,006,054
<b>Operating income before taxes</b>	-77,469,000	-106,352,000	-180,206,000
<b>Cash Flow</b>	-33,461,000	-79,529,000	-157,692,000
<b>Net interest income</b>	14,222,000	5,118,000	-
<b>Research and development expenses</b>	49,641,000	44,988,000	51,139,000
<b>Income taxes</b>	551,000	1,828,000	760,000
<b>Result from investments in subsidiaries, associates and other</b>	0	0	0
<b>Revenues per employee</b>	545,436	416,521	141,725

## Board of Directors

Daniel Billen	Chairman of Supervisory Board
Brinda Balakrishnan	Member of Supervisory Board
David Jaynee	Member of Supervisory Board
Karen Smith	Member of Supervisory Board
Robert Foster	Member of Supervisory Board
Jeffrey Bailey	Member of Supervisory Board
Jill Leversage	Member of Supervisory Board
R. MacKay-Dunn	Member of Supervisory Board

## Members of Management Board